Pharmacom Biovet Stock Gross Profit
| PHMB Stock | USD 0.0001 0.00 0.00% |
Pharmacom Biovet fundamentals help investors to digest information that contributes to Pharmacom Biovet's financial success or failures. It also enables traders to predict the movement of Pharmacom Stock. The fundamental analysis module provides a way to measure Pharmacom Biovet's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmacom Biovet stock.
| Last Reported | Projected for Next Year |
Pharmacom | Gross Profit |
Pharmacom Biovet Company Gross Profit Analysis
Pharmacom Biovet's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Pharmacom Biovet reported 0.0 of gross profit. This is 100.0% lower than that of the Health Care Providers & Services sector and about the same as Health Care (which currently averages 0.0) industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Pharmacom Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmacom Biovet's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmacom Biovet could also be used in its relative valuation, which is a method of valuing Pharmacom Biovet by comparing valuation metrics of similar companies.Pharmacom Biovet is currently under evaluation in gross profit category among its peers.
Pharmacom Fundamentals
| Current Valuation | 1.08 M | ||||
| Net Income | (556.18 K) | ||||
| Total Debt | 61.54 K | ||||
| Beta | 168.8 | ||||
| Market Capitalization | 1.08 M | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) | ||||
| Working Capital | (29 K) | ||||
| Current Liabilities | 29 K | ||||
| Net Asset | 112.36 K |
About Pharmacom Biovet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacom Biovet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacom Biovet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacom Biovet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Pharmacom Biovet Piotroski F Score and Pharmacom Biovet Altman Z Score analysis. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.